A causal role for ERG in neoplastic transformation of prostate epithelium

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 6, 2008, Pages 2105-2110

  Klezovitch, Olga ^a   Risk, Michael ^a,b   Coleman, Ilsa ^a   Lucas, Jared M ^a   Null, Manda ^a   True, Lawrence D ^c   Nelson, Peter S ^a,b,c   Vasioukhin, Valeri ^a,c  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

ETS family; Mouse models; Prostate cancer; Prostatic intrepithelial neoplasia (PIN)

Indexed keywords

TRANSCRIPTION FACTOR ERG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL HETEROGENEITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTATE EPITHELIUM; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR GROWTH; UPREGULATION;

ANIMALS; CELL LINE; CELL TRANSFORMATION, NEOPLASTIC; DNA-BINDING PROTEINS; EPITHELIAL CELLS; HUMANS; MALE; MICE; PROSTATE; PROSTATIC INTRAEPITHELIAL NEOPLASIA; RNA, MESSENGER; SERINE ENDOPEPTIDASES; TRANS-ACTIVATORS;

MUS MUSCULUS;

EID: 41149097040     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0711711105     Document Type: Article

References (24)

1. Tomlins SA, et al. (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310:644-648.
2. Perner S, et al. (2007) TMPRSS2-ERG fusion prostate cancer: An early molecular event associated with invasion. Am J Surg Pathol 31:882-888.
3. Perner S, et al. (2006) TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 66:8337-8341.
4. Demichelis F, et al. (2007) TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 26:4596-4599.
5. Petrovics G, et al. (2005) Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 24:3847-3852.
6. Tu JJ, et al. (2007) Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: Frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues. Mod Pathol 20:921-928.
7. Lapointe J, et al. (2004) Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 101:811-816.
8. Glinsky GV, Glinskii AB, Stephenson AJ, Hoffman RM, Gerald WL (2004) Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest 113:913-923.
9. True L, et al. (2006) A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proc Natl Acad Sci USA 103:10991-10996.
10. Iljin K, et al. (2006) TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Cancer Res 66:10242-10246.
11. Zou J, et al. (2005) The oncogenic TLS-ERG fusion protein exerts different effects in hematopoietic cells and fibroblasts. Mol Cell Biol 25:6235-6246.
12. Deneen B, et al. (2003) PIM3 proto-oncogene kinase is a common transcriptional target of divergent EWS/ETS oncoproteins. Mol Cell Biol 23:3897-3908.
13. Lin DW, et al. (2006) Influence of surgical manipulation on prostate gene expression: Implications for molecular correlates of treatment effects and disease prognosis. J Clin Oncol 24:3763-3770.
14. Klezovitch O, et al. (2004) Hepsin promotes prostate cancer progression and metastasis. Cancer Cell 6:185-195.
15. Zhang J, Thomas TZ, Kasper S, Matusik RJ (2000) A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo. Endocrinology 141:4698-4710.
16. Bostwick DG, Brawer MK (1987) Prostatic intraepithelial neoplasia and early invasion in prostate cancer. Cancer 59:788-794.
17. Ro JY, Amin MB, Sahin AA, Ayala AG (1995) in Diagnostic Histopathology of Tumours, ed Fletcher CDM (Churchill Livingstone, Edinburgh), pp 755-761.
18. Wang S, et al. (2006) Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation. Proc Natl Acad Sci USA 103:1480-1485.
19. Tomlins SA, et al. (2007) Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 448:595-599.
20. Sambrook J, Russell DW (2001) Molecular Cloning: A Laboratory Manual (Cold Spring Harbor Lab Press, Cold Spring Harbor, NY, pp 7.42-7.44).
21. Subramanian A, et al. (2005) Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102:15545-15550.
22. Vasioukhin V, Bauer C, Degenstein L, Wise B, Fuchs E (2001) Hyperproliferation and defects in epithelial polarity upon conditional ablation of α-catenin in skin. Cell 104:605-617.
23. Hayward SW, et al. (1995) Establishment and characterization of an immortalized but nontransformed human prostate epithelial cell line: BPH-1. In Vitro Cell Dev Biol 31:14-24.
24. Miwa S, et al. (2005) The bisphosphonate YM529 inhibits osteolytic and osteoblastic changes and CXCR-4-induced invasion in prostate cancer. Cancer Res 65:8818-8825.